| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D265-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D265-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-538
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-535
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D265-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D265-18 |
| filingDate |
2011-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2014-01-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2014500330-A |
| titleOfInvention |
Bicyclic PKM2 activator |
| abstract |
Described herein are compounds and compositions comprising compounds such as Formula (I) that activate pyruvate kinase M2 (PKM2). Also described herein are methods of using compounds that activate PKM2 in the treatment of cancer. In one embodiment, the present invention modulates the level of PKM2 activity and / or glycolysis (eg, downregulates PKM2 in a patient) in a patient in need of modulation of the level of PKM2 activity and / or glycolysis. It features a method of modulating the endogenous capacity of a cell). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019521090-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019206587-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7213775-B2 |
| priorityDate |
2010-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |